Ningxia Zhongke Biotechnology , Ltd. EBIT

As of the most recent data (June 2026), 600165.SS shows a EBIT of $-80M. That compares with $-250M in the prior-year period — up 68.2% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 600165.SS's EBIT is now $-80M (was $-250M) — a 68.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ningxia Zhongke Biotechnology , Ltd. is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Ningxia Zhongke Biotechnology , Ltd. is at $-80M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 600165.SS stacks up against individual peers as well.

Tracking 600165.SS's ebit over time shows whether Ningxia Zhongke Biotechnology , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $-80M That compares with $-250M in the prior-year period — up 68.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Ningxia Zhongke Biotechnology , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-80M) with ownership activity and broader fundamentals.